Procedureless Gastric Balloon Encourages Weight Loss
By HospiMedica International staff writers Posted on 23 Dec 2015 |

Image: The Elipse procedureless gastric balloon (Photo courtesy of Allurion Technologies).S
An innovative gastric balloon offers an alternative treatment option for overweight and obese individuals.
The Elipse procedureless gastric balloon is a thin, flexible polymer film balloon that is delivered in a swallowable capsule, thus eliminating the need for surgery, endoscopy, or anesthesia. Once in position, it is filled with liquid through a thin delivery catheter, which is then detached by tugging. The gastric balloon remains in the stomach for four months, after which it automatically empties and is excreted naturally from the body. The Elipse will be offered by physicians in conjunction with a medically supervised diet and exercise program.
The Elipse has undergone clinical studies in people with a body mass index (BMI) of 27-40 kg/m2. Study findings indicated an average weight loss of 10 kilograms, with participants losing 37% of their excess weight and eight centimeters off their waist circumference over the four month treatment period. Participants also saw improvements in triglyceride and hemoglobin HbA1c levels, and all balloons were safely and naturally excreted. The Elipse procedureless gastric balloon is a product of Allurion Technologies (Wellesley, MA, USA), and has received the European Community CE marking of approval.
“Excess weight often has a profound impact on health and quality of life, including work, relationships, and self-perception. But of nearly two billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options,” said Shantanu Gaur, MD, co-founder and chief scientific officer of Allurion Technologies. “Weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them.”
“Following six years of development, we are very excited to enter the next phase of our company's growth,” said Jonathan Wecker, CEO of Allurion Technologies. “I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipse a reality.”
Related Links:
Allurion Technologies
The Elipse procedureless gastric balloon is a thin, flexible polymer film balloon that is delivered in a swallowable capsule, thus eliminating the need for surgery, endoscopy, or anesthesia. Once in position, it is filled with liquid through a thin delivery catheter, which is then detached by tugging. The gastric balloon remains in the stomach for four months, after which it automatically empties and is excreted naturally from the body. The Elipse will be offered by physicians in conjunction with a medically supervised diet and exercise program.
The Elipse has undergone clinical studies in people with a body mass index (BMI) of 27-40 kg/m2. Study findings indicated an average weight loss of 10 kilograms, with participants losing 37% of their excess weight and eight centimeters off their waist circumference over the four month treatment period. Participants also saw improvements in triglyceride and hemoglobin HbA1c levels, and all balloons were safely and naturally excreted. The Elipse procedureless gastric balloon is a product of Allurion Technologies (Wellesley, MA, USA), and has received the European Community CE marking of approval.
“Excess weight often has a profound impact on health and quality of life, including work, relationships, and self-perception. But of nearly two billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options,” said Shantanu Gaur, MD, co-founder and chief scientific officer of Allurion Technologies. “Weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them.”
“Following six years of development, we are very excited to enter the next phase of our company's growth,” said Jonathan Wecker, CEO of Allurion Technologies. “I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipse a reality.”
Related Links:
Allurion Technologies
Latest Surgical Techniques News
- Pioneering Sutureless Coronary Bypass Technology to Eliminate Open-Chest Procedures
- Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures
- World's First AI Surgical Guidance Platform Allows Surgeons to Measure Success in Real-Time
- AI-Generated Synthetic Scarred Hearts Aid Atrial Fibrillation Treatment
- New Class of Bioadhesives to Connect Human Tissues to Long-Term Medical Implants
- New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation
- Minimally Invasive Valve Repair Reduces Hospitalizations in Severe Tricuspid Regurgitation Patients
- Tiny Robotic Tools Powered by Magnetic Fields to Enable Minimally Invasive Brain Surgery
- Magnetic Tweezers Make Robotic Surgery Safer and More Precise
- AI-Powered Surgical Planning Tool Improves Pre-Op Planning
- Novel Sensing System Restores Missing Sense of Touch in Minimally Invasive Surgery
- Headset-Based AR Navigation System Improves EVD Placement
- Higher Electrode Density Improves Epilepsy Surgery by Pinpointing Where Seizures Begin
- Open-Source Tool Optimizes Placement of Visual Brain Implants
- Easy-To-Apply Gel Could Prevent Formation of Post-Surgical Abdominal Adhesions
- Groundbreaking Leadless Pacemaker to Prevent Invasive Surgeries for Children
Channels
Critical Care
view channel
Ingestible Smart Capsule for Chemical Sensing in the Gut Moves Closer to Market
Intestinal gases are associated with several health conditions, including colon cancer, irritable bowel syndrome, and inflammatory bowel disease, and they have the potential to serve as crucial biomarkers... Read more
Novel Cannula Delivery System Enables Targeted Delivery of Imaging Agents and Drugs
Multiphoton microscopy has become an invaluable tool in neuroscience, allowing researchers to observe brain activity in real time with high-resolution imaging. A crucial aspect of many multiphoton microscopy... Read more
Novel Intrabronchial Method Delivers Cell Therapies in Critically Ill Patients on External Lung Support
Until now, administering cell therapies to patients on extracorporeal membrane oxygenation (ECMO)—a life-support system typically used for severe lung failure—has been nearly impossible.... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Expanded Collaboration to Transform OR Technology Through AI and Automation
The expansion of an existing collaboration between three leading companies aims to develop artificial intelligence (AI)-driven solutions for smart operating rooms with sophisticated monitoring and automation.... Read more